Akoya Biosciences (AKYA) announced the availability of a new assay designed to advance antibody-drug conjugate development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the PhenoCode Discovery IO60 panel-Akoya’s flagship ultrahigh-plex immuno-oncology solution-at the American Association for Cancer Research, AACR, 2025 Annual Meeting, taking place April 25-30 in Chicago, Illinois.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences, Enable Medicine launch single-cell spatial proteomics atlas
- Akoya Biosciences, STCC partner on SUPER study for cancer immunophenotyping
- Akoya Biosciences price target lowered to $1.65 from $2.40 at Piper Sandler
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion
- Tikvah intends to vote against Quanterix’s proposed merger with Akoya